poisar

Filings · News reference

Cue Biopharma Files Prospectus For Resale Of 1,505,570 Shares, Including 87,500 Underlying Pre-Funded Warrants, Issued In $50M July Private Placement

Benzinga Newsdesk

https://www.sec.gov/Archives/edgar/data/1645460/000119312526346867/d136967ds3.htm

More filings newsConnected markets

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

CUE
Source
benzinga
Observed
Checked
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading

  1. Not Specified

    Lift Therapeutics Appoints Daniel Passeri as Chief Executive Officer

    Lift Therapeutics announced the appointment of Daniel Passeri as CEO, bringing over 30 years of oncology drug development experience. Bo Rode Hansen transitions from Interim CEO to President and Board member. The company is preparing to advance its lead immuno-Modulatory Alpha Neutrophil (iMAN) program into first-in-human clinical studies in early 2027.

    CRISCUE
  3. SEC EDGAR

    8-K filing — Cue Biopharma, Inc. (CUE)

    Filed: 2026-09-21 AccNo: 0001193125-26-396094 Size: 10 MB Item 7.01: Regulation FD Disclosure Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits

    CUE